Format

Send to

Choose Destination
Biomaterials. 2018 Sep;178:193-203. doi: 10.1016/j.biomaterials.2018.06.024. Epub 2018 Jun 18.

Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors.

Author information

1
Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.
2
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06511, USA.
3
Department of Chemistry "G. Ciamician" and INSTM UdR of Bologna, University of Bologna, 40126, Bologna, Italy.
4
Department of Biomedical Engineering, Yale University, West Haven, CT, 06516, USA.
5
Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA. Electronic address: mark.saltzman@yale.edu.

Abstract

Intracranial delivery of therapeutic agents is limited by penetration beyond the blood-brain barrier (BBB) and rapid metabolism of the drugs that are delivered. Convection-enhanced delivery (CED) of drug-loaded nanoparticles (NPs) provides for local administration, control of distribution, and sustained drug release. While some investigators have shown that repeated CED procedures are possible, longer periods of sustained release could eliminate the need for repeated infusions, which would enhance safety and translatability of the approach. Here, we demonstrate that nanoparticles formed from poly(ethylene glycol)-poly(ω-pentadecalactone-co-p-dioxanone) block copolymers [PEG-poly(PDL-co-DO)] are highly efficient nanocarriers that provide long-term release: small nanoparticles (less than 100 nm in diameter) continuously released a radiosensitizer (VE822) over a period of several weeks in vitro, provided widespread intracranial drug distribution during CED, and yielded significant drug retention within the brain for over 1 week. One advantage of PEG-poly(PDL-co-DO) nanoparticles is that hydrophobicity can be tuned by adjusting the ratio of hydrophobic PDL to hydrophilic DO monomers, thus making it possible to achieve a wide range of drug release rates and drug distribution profiles. When administered by CED to rats with intracranial RG2 tumors, and combined with a 5-day course of fractionated radiation therapy, VE822-loaded PEG-poly(PDL-co-DO) NPs significantly prolonged survival when compared to free VE822. Thus, PEG-poly(PDL-co-DO) NPs represent a new type of versatile nanocarrier system with potential for sustained intracranial delivery of therapeutic agents to treat brain tumors.

KEYWORDS:

Convection-enhanced delivery; Intracranial; Nanoparticles; PEG; Radiosensitizer

PMID:
29936153
PMCID:
PMC6082184
[Available on 2019-09-01]
DOI:
10.1016/j.biomaterials.2018.06.024

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center